Banarian Nordic Res (BVNKF) 47.0000 $BVNKF
Bavarian Nordic reports successful results from two studies of Imvamune smallpox vaccine
Seeking Alpha - at Seeking Alpha - Wed May 13, 8:39AM CDT
Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE(R) Smallpox Vaccine
Thomson Reuters ONE - Wed May 13, 12:31AM CDT
- Completion of first Phase 3 study to support a Biologics License Application for liquid-frozen IMVAMUNE
Bavarian Nordic Announces Presentation of Preliminary Phase 1 Results for the Ebola Prime-Boost Vaccine Regimen of MVA-BN(r) Filo and Janssen's AdVac(r) technology
GlobeNewswire - Tue May 12, 1:04PM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces that preliminary results from a Phase 1 first-in-human study of the Ebola prime-boost vaccine regimen of Bavarian Nordic's ("The Company"
MVA-BN Filo vaccine and the AdVac vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson were presented today by Janssen at a meeting of the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee as part of discussions on the development and licensure of Ebola vaccines.
JNJ: 102.30 (+0.47)
Bavarian Nordic awash in money to fund Ebola and prostate cancer programs
Seeking Alpha - at Seeking Alpha - Tue May 12, 11:13AM CDT
JNJ: 102.30 (+0.47), BMY: 67.64 (+0.19)
Bavarian Nordic Granted EUR 50 Million Loan from The European Investment Bank
Thomson Reuters ONE - Tue May 12, 5:09AM CDT
- The Company upgrades its expectations to year end cash preparedness
Bavarian Nordic Announces Interim Results for the First Three Months of 2015
Thomson Reuters ONE - Tue May 05, 12:43AM CDT
KVISTGAARD, Denmark, May 5, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first three months of 2015.
Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 23 April 2015
Thomson Reuters ONE - Thu Apr 23, 2:12PM CDT
KVISTGAARD, Denmark - April 23, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today held the Annual General Meeting with the results as follows:
Bavarian Nordic to Present at Needham & Company's 14th Annual Healthcare Conference in New York City
Thomson Reuters ONE - Tue Apr 14, 10:30AM CDT
KVISTGAARD, Denmark - April 14, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Paul Chaplin, President & Chief Executive Officer will provide a corporate presentation at Needham & Company's 14th Annual Healthcare Conference in New York City on Wednesday, April 15, 2015 at 5:00 PM EST.
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 5.77 (-0.40), BIIB: 391.24 (-3.11), NWBO: 8.12 (+0.07), ADXS: 20.08 (+1.11), ADRO: 31.47 (-1.40), AMGN: 162.36 (+0.38), GSK: 44.77 (-0.22), ONTY: 2.43 (+0.41), IMUC: 0.48 (+0.01), MACK: 12.66 (+0.34), GBIM: 7.51 (-0.17), ARGS: 7.68 (+0.09), BLCM: 23.02 (-1.37), NLNK: 39.69 (+1.57)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.68 (-0.01), NBS: 2.38 (+0.07), OSIR: 17.29 (-0.18), BCLI: 3.66 (-0.04), MDVN: 122.90 (-0.47), INO: 7.97 (-0.02), CYTX: 0.66 (-0.02), STEM: 0.62 (+0.01), JUNO: 43.37 (-1.52), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04), BLUE: 154.42 (-2.98), VRTX: 126.21 (+3.21), AMGN: 162.36 (+0.38), KERX: 10.33 (+0.11), OMER: 20.88 (-0.01), KITE: 50.02 (-2.24), GILD: 109.30 (+0.56), MRK: 60.23 (+0.45), TEVA: 60.23 (-0.99)
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
Thomson Reuters ONE - Fri Mar 27, 3:26AM CDT
KVISTGAARD, Denmark, March 27, 2015 - Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the annual General Meeting to be held on
Bavarian Nordic A/S - Major Shareholder Announcement
Thomson Reuters ONE - Fri Mar 13, 4:36PM CDT
KVISTGAARD, Denmark, March 13, 2015 - Pursuant to Section 29 of the Danish Securities Trading Act it is hereby announced, that ATP has decreased its ownership in Bavarian Nordic and now holds 2,741,918 shares in Bavarian Nordic corresponding to 9.91 % of the share capital and voting rights in Bavarian Nordic.
Bavarian Nordic Announces 2014 Full Year Results
Thomson Reuters ONE - Wed Mar 11, 1:38AM CDT
KVISTGAARD, Denmark, March 11, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today published its 2014 annual report. Revenue was DKK 1,217 million / USD 175 million (DKK 1,213 million / USD 175 million in 2013). The Group recorded an EBIT of DKK 17 million / USD 2 million (DKK 33 million / USD 5 million in 2013) and a net profit of DKK 26 million / USD 4 million (DKK 47 million loss / USD 7 million loss). Revenue and results were in line with the expectations for the year. At year-end 2014, the cash preparedness was DKK 1,000 million / USD 144 million (DKK 652 million / USD 94 million as of 31 December 2013).
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
PR Newswire - Fri Jan 16, 5:29AM CST
Johnson & Johnson (NYSE: JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than EUR 100 million from the Ebola+ programme to support the development, manufacturing and patient education for the vaccine regimen.
JNJ: 102.30 (+0.47)
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN(R) Filo and Janssen's AdVac(R) technology
Thomson Reuters ONE - Tue Jan 06, 1:00AM CST
- First human trial of the MVA-BN(R) Filo/AdVac(R) preventative Ebola vaccine regimen initiated in the UK
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
PR Newswire - Tue Jan 06, 1:00AM CST
Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.
JNJ: 102.30 (+0.47)
Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC(R) in Prostate Cancer
GlobeNewswire - Wed Dec 10, 12:41AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has reached the planned enrollment of 1,200 patients in the PROSPECT Phase 3 clinical study of its targeted active immunotherapy candidate, PROSTVAC(R), in the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Patients were enrolled at 214 sites in 15 countries.
Bavarian Nordic reports successful results from two studies of Imvamune smallpox vaccine
Seeking Alpha - at Seeking Alpha - Wed May 13, 8:39AM CDT
Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE(R) Smallpox Vaccine
Thomson Reuters ONE - Wed May 13, 12:31AM CDT
- Completion of first Phase 3 study to support a Biologics License Application for liquid-frozen IMVAMUNE
Bavarian Nordic Announces Presentation of Preliminary Phase 1 Results for the Ebola Prime-Boost Vaccine Regimen of MVA-BN(r) Filo and Janssen's AdVac(r) technology
GlobeNewswire - Tue May 12, 1:04PM CDT
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces that preliminary results from a Phase 1 first-in-human study of the Ebola prime-boost vaccine regimen of Bavarian Nordic's ("The Company"
MVA-BN Filo vaccine and the AdVac vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson were presented today by Janssen at a meeting of the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee as part of discussions on the development and licensure of Ebola vaccines. JNJ: 102.30 (+0.47)
Bavarian Nordic awash in money to fund Ebola and prostate cancer programs
Seeking Alpha - at Seeking Alpha - Tue May 12, 11:13AM CDT
JNJ: 102.30 (+0.47), BMY: 67.64 (+0.19)
Bavarian Nordic Granted EUR 50 Million Loan from The European Investment Bank
Thomson Reuters ONE - Tue May 12, 5:09AM CDT
- The Company upgrades its expectations to year end cash preparedness
Bavarian Nordic Announces Interim Results for the First Three Months of 2015
Thomson Reuters ONE - Tue May 05, 12:43AM CDT
KVISTGAARD, Denmark, May 5, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first three months of 2015.
Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 23 April 2015
Thomson Reuters ONE - Thu Apr 23, 2:12PM CDT
KVISTGAARD, Denmark - April 23, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today held the Annual General Meeting with the results as follows:
Bavarian Nordic to Present at Needham & Company's 14th Annual Healthcare Conference in New York City
Thomson Reuters ONE - Tue Apr 14, 10:30AM CDT
KVISTGAARD, Denmark - April 14, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Paul Chaplin, President & Chief Executive Officer will provide a corporate presentation at Needham & Company's 14th Annual Healthcare Conference in New York City on Wednesday, April 15, 2015 at 5:00 PM EST.
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 5.77 (-0.40), BIIB: 391.24 (-3.11), NWBO: 8.12 (+0.07), ADXS: 20.08 (+1.11), ADRO: 31.47 (-1.40), AMGN: 162.36 (+0.38), GSK: 44.77 (-0.22), ONTY: 2.43 (+0.41), IMUC: 0.48 (+0.01), MACK: 12.66 (+0.34), GBIM: 7.51 (-0.17), ARGS: 7.68 (+0.09), BLCM: 23.02 (-1.37), NLNK: 39.69 (+1.57)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.68 (-0.01), NBS: 2.38 (+0.07), OSIR: 17.29 (-0.18), BCLI: 3.66 (-0.04), MDVN: 122.90 (-0.47), INO: 7.97 (-0.02), CYTX: 0.66 (-0.02), STEM: 0.62 (+0.01), JUNO: 43.37 (-1.52), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04), BLUE: 154.42 (-2.98), VRTX: 126.21 (+3.21), AMGN: 162.36 (+0.38), KERX: 10.33 (+0.11), OMER: 20.88 (-0.01), KITE: 50.02 (-2.24), GILD: 109.30 (+0.56), MRK: 60.23 (+0.45), TEVA: 60.23 (-0.99)
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
Thomson Reuters ONE - Fri Mar 27, 3:26AM CDT
KVISTGAARD, Denmark, March 27, 2015 - Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the annual General Meeting to be held on
Bavarian Nordic A/S - Major Shareholder Announcement
Thomson Reuters ONE - Fri Mar 13, 4:36PM CDT
KVISTGAARD, Denmark, March 13, 2015 - Pursuant to Section 29 of the Danish Securities Trading Act it is hereby announced, that ATP has decreased its ownership in Bavarian Nordic and now holds 2,741,918 shares in Bavarian Nordic corresponding to 9.91 % of the share capital and voting rights in Bavarian Nordic.
Bavarian Nordic Announces 2014 Full Year Results
Thomson Reuters ONE - Wed Mar 11, 1:38AM CDT
KVISTGAARD, Denmark, March 11, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today published its 2014 annual report. Revenue was DKK 1,217 million / USD 175 million (DKK 1,213 million / USD 175 million in 2013). The Group recorded an EBIT of DKK 17 million / USD 2 million (DKK 33 million / USD 5 million in 2013) and a net profit of DKK 26 million / USD 4 million (DKK 47 million loss / USD 7 million loss). Revenue and results were in line with the expectations for the year. At year-end 2014, the cash preparedness was DKK 1,000 million / USD 144 million (DKK 652 million / USD 94 million as of 31 December 2013).
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
PR Newswire - Fri Jan 16, 5:29AM CST
Johnson & Johnson (NYSE: JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than EUR 100 million from the Ebola+ programme to support the development, manufacturing and patient education for the vaccine regimen.
JNJ: 102.30 (+0.47)
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN(R) Filo and Janssen's AdVac(R) technology
Thomson Reuters ONE - Tue Jan 06, 1:00AM CST
- First human trial of the MVA-BN(R) Filo/AdVac(R) preventative Ebola vaccine regimen initiated in the UK
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
PR Newswire - Tue Jan 06, 1:00AM CST
Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.
JNJ: 102.30 (+0.47)
Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC(R) in Prostate Cancer
GlobeNewswire - Wed Dec 10, 12:41AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has reached the planned enrollment of 1,200 patients in the PROSPECT Phase 3 clinical study of its targeted active immunotherapy candidate, PROSTVAC(R), in the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Patients were enrolled at 214 sites in 15 countries.
